Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic

INTRODUCTION: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted accelerated vaccine development of novel messenger RNA (mRNA)-based vaccines by Moderna and Pfizer, which received FDA Emergency Use Authorization in December 2020. The purpose of this study was to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts-McCarthy, Erin, Buck, Philip O., Smith-Ray, Renae L., Van de Velde, Nicolas, Singh, Tanya, Mansi, James, Shah, Amy, Taitel, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172969/
https://www.ncbi.nlm.nih.gov/pubmed/37296016
http://dx.doi.org/10.1016/j.vaccine.2023.03.076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172969/
https://www.ncbi.nlm.nih.gov/pubmed/37296016
http://dx.doi.org/10.1016/j.vaccine.2023.03.076

Ejemplares similares